ANO31905 in Combination With Chemotherapy for CLDN18.2-Positive Locally Advanced Unresectable or Metastatic Pancreatic Cancer
Anova Innovation Limited
Anova Innovation Limited
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
BigHat Biosciences, Inc.
M.D. Anderson Cancer Center
UNC Lineberger Comprehensive Cancer Center
Catholic University of the Sacred Heart
Recurv Pharma Inc
Bristol-Myers Squibb
ImmunityBio, Inc.
Universidad Europea de Madrid
University of Miami
University of Vermont
Sun Yat-sen University
Gustave Roussy, Cancer Campus, Grand Paris
Centre Antoine Lacassagne
Case Comprehensive Cancer Center
Casa di Cura Dott. Pederzoli
Zhejiang University
First Affiliated Hospital of Wenzhou Medical University
University of Rochester
University of Rochester
FutureGen Biopharmaceutical (Beijing) Co., Ltd
Unity Health Toronto
M.D. Anderson Cancer Center
Hospital Universitari de Bellvitge
HealthPartners Institute
Second Life Therapeutics
IMGT Co., Ltd.
Fudan University
Genfleet Therapeutics (Shanghai) Inc.
Alpha Tau Medical LTD.
Jinling Hospital, China
GE Healthcare
Shanghai Zhongshan Hospital
West China Hospital
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Shandong Cancer Hospital and Institute
Shandong Cancer Hospital and Institute
The Second Affiliated Hospital of Shandong First Medical University
University Hospital Tuebingen
Clinica Universidad de Navarra, Universidad de Navarra
Shanghai Miracogen Inc.
Peking Union Medical College Hospital
Case Comprehensive Cancer Center
Fudan University
Shanghai Zhongshan Hospital
West China Hospital
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Huazhong University of Science and Technology
TME Pharma AG